StemCell Therapy

The company said its RA 360 solution will support employees to reduce or maintain their current level of drug use

eWellness Healthcare Corporation (), the pioneer in physical therapy telehealth treatments, announced Tuesday that it is developing a new rheumatoid arthritis treatment platform called RA360.

In a statement, the Culver City, California-based company, said the new platform is expected to be available in the first quarter of 2020.

Rheumatoid arthritis and related autoimmune disorders are the leading cause of illness and disability in the US.

In 2019, one in four Americans has arthritis, or one of its 100 related autoimmune disorders, according to the company.

Those with rheumatoid arthritis will need to go on disability or stop work entirely within 2 years of onset, the group added.

However, the company said that its innovative RA360 solution will support employees to reduce or maintain their current level of theraputic drug use.

The company notes that costs associated with arthritis hit $128 billion in 2005, while other studies put the cost closer to $353 billion when payouts, lost wages and other associated medical costs were stacked up.

According to eWellness Healthcare, a reduction in symptoms will alleviate stress on the health care system and the employer.

Arthritis isnt an individual problem, its everyones problem. The damage cannot be undone but can be managed, the company added, while making the case that its new rheumatoid arthritis treatment platform RA360 was part of the solution.

eWellness Healthcare is the first physical therapy telehealth company to offer real-time distance monitored assessments and treatments.

Contact Uttara Choudhury at[emailprotected]

Follow her onTwitter:@UttaraProactive

Continued here:
eWellness Healthcare developing new rheumatoid arthritis treatment platform RA360 - Proactive Investors USA & Canada

This entry was posted on November 18, 2019 at 4:45 am and is filed under Arthritis. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |